Key facts
- Cellestial Health’s last known valuation is $1.9M (May 2025).
- It has raised $680K.
- Notable investors include SFC Capital, Zinc, Iain Pelling, Parkinson's UK, University of Cambridge — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cellestial Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellestial Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellestial Health
Developer of a brain-penetrant small molecule therapeutic designed to slow the progression of neurodegenerative diseases by targeting astrocytes. The company offers innovative compounds that stabilize astrocytic networks, enabling neurologists to provide early treatment for patients diagnosed with conditions like Parkinson's disease, improving long-term brain health.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2023
- Employees
- 3
- Website
- cellestialhealth.com/
- Ownership
- Privately Held (backing)
Cellestial Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellestial Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellestial Health in its N-PORT filings yet. We sweep new filings monthly.